Mediar Therapeutics is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis and restore long-term organ function. The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs. Mediar was founded by Partners Innovation Fund, Massachusetts General Hospital and Brigham & Women’s Hospital.
- Meredith Fisher CEO
- Paul J. Yaworsky, Ph.D. Chief Scientific Officer
- Daniel Tavares Sr. Director
- Christopher Espelin Director of Pharmacology and Translational Biology